EP 06 - The Future of Biologics: How Strategic CROs are Powering the Next Generation of Clinical Research

In this episode of The Bridge with Pavlina Walter, I was joined by my business partner, Dr. Peter M. Kovacs, and Jiri Raska, Chief Commercial Officer of Quinta Analytica, a Czech-based CRO shaping the future of biologics and clinical research. We explore how strategic CRO partnerships accelerate innovation, from analytical chemistry to clinical trials. Key themes: • The rise of biologics and biosimilars in global healthcare. • Why small biotech startups need integrated CRO partners. • Regulatory realities and Europe’s path to faster approvals. • How Central Europe is becoming a hub for biologics and ADCs. • The human side of research: trust, communication, and collaboration. Subscribe to The Bridge for more conversations connecting science, technology, and humanity. Timecode: 00:00 Introduction to Jiri and Quinta Analytica 01:09 Jiri's Background and Passion for Chemistry 01:56 Transition to Business Development 03:43 Current Trends in Biologics and Biosimilars 05:57 Challenges and Opportunities in Clinical Studies 09:17 Supporting Small Biotech Startups 13:08 Customer Success Management 14:47 Expansion and Collaboration 16:43 Future of Personalized Medicine 19:26 Regulatory Challenges in Europe 23:58 Ostrava Subsidiary and Cross-Border Recruitment 27:00 Future Directions for Quinta Analytica 29:50 Jiri's Personal Career Aspirations 31:49 Conclusion and Final Thoughts Links: Pavlina Walter: https://www.linkedin.com/in/pavlinawalter/ Website: PavlinaWalter.com Guests: Jiri Raska: https://www.linkedin.com/in/jiri-raska-pharma/ Peter M. Kovacs: https://www.linkedin.com/in/petermkovacs/